GNTANasdaqBiological Products, (No Diagnostic Substances)
Genenta Science S.p.A.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026
$0.66−0.02 (-2.40%)
Close on Oct 19, 2026
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -32.9% | -38.0% | |
| Return on assets | – | – | -28.0% | |
| Current ratio | – | 7.09 | 14.16 | |
| Diluted shares | – | – | 20M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Genenta Science S.p.A. generated €38.69M from operations and spent €61.96K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
€38.69M
Used
€61.96K
Capital expenditure€61.96K100%Dividends€00%Share buybacks€00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-€6.53M
- Cash generatingOperating cash flow above zero-€6.87M
- Return on assets improvedROA up on the prior year-39.9% → -44.0%
- Earnings backed by cashOperating cash flow above net income-€6.87M vs -€6.53M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose6.89 → 14.16
- No dilutionShare count did not rise18M → 20M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –